[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Spur Therapeutics\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":52},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100054053","phase-3-a-gaucher-disease-gene-therapy-trial-with-flt201-100054053",false,"NCT07223944","A Gaucher Disease Gene Therapy Trial With FLT201","A Phase 3 Safety and Efficacy Trial of FLT201 Gene Therapy in Patients With Gaucher Disease Type 1","GALILEO-3","Key Inclusion Criteria:\n\n* Aged ≥18 years at time of screening.\n* Clinical diagnosis of Gaucher disease type 1\n* Stable hemoglobin concentration at baseline\n* Stable platelet count at baseline\n* Receiving ERT or SRT without interruption for at least 2 years\n\nKey Exclusion Criteria:\n\n* Diagnosed or suspected Gaucher disease type 2 or type 3\n* Positive for AAVS3 neutralizing antibodies.\n* Abnormal lab values, conditions or diseases that would make the participant unsuitable for the study\n* Positive pregnancy test or lactating\n* History of hematopoietic stem cell transplant (HSCT)\u002Fbone marrow transplant or any solid organ transplant.\n* History of receiving any gene therapy or cell therapy.\n* History of total splenectomy. Note: Additional protocol defined Inclusion and Exclusion criteria apply","ALL","18 Years",{"count":20,"type":21},45,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","This study is a Phase 3, non-randomized, multicenter, efficacy and safety study in adult patients with Gaucher disease Type 1, on stable treatment with enzyme replacement therapy (ERT) or substrate reduction therapy (SRT) for at least 2 years. The study aims to confirm the efficacy and safety of FLT201 in this population after discontinuation of ERT\u002FSRT.",[27],"Gaucher Disease Type 1","RECRUITING","2026-07-10",{"date":31,"type":32},"2026-07-13","ACTUAL",{"date":34,"type":32},"2026-04-07",{"date":36,"type":21},"2032-10-01",{"name":38,"class":39},"Spur Therapeutics","INDUSTRY",33,{"id":42,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":43,"targetDuration":4,"studyType":22,"phases":44,"briefSummary":25,"conditions":45,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":46,"lastUpdatePostDateStruct":47,"startDateStruct":49,"completionDateStruct":50,"leadSponsor":51,"locationsCount":40},"100610158",{"count":20,"type":21},[24],[27],"2026-06-22",{"date":48,"type":32},"2026-06-23",{"date":34,"type":32},{"date":36,"type":21},{"name":38,"class":39},""]